Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: An issue revisited

Prenatal Diagnosis

Volumn 22, Issue 10, 2002, Pages 874-876

  Spencer, Kevin ^a  

^a HAROLD WOOD HOSPITAL   (United Kingdom)

Author keywords

Counselling; Free hCG; Nuchal translucency; PAPP A; Prenatal screening; Trisomy 21

Indexed keywords

BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ANEUPLOIDY; ARTICLE; DISEASE MARKER; DOWN SYNDROME; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HIGH RISK PREGNANCY; HUMAN; MATERNAL AGE; MATERNAL SERUM; PATIENT COUNSELING; PRIORITY JOURNAL; SCREENING;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; GESTATIONAL AGE; HUMANS; MATERNAL AGE; MIDDLE AGED; NECK; PARITY; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; RECURRENCE; RISK FACTORS;

EID: 0036797519     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.430     Document Type: Article

References (13)

1. Dar H, Merksamer R, Berdichevsky D, David M. 1996. Maternal serum marker levels in consecutive pregnancies: a possible genetic predisposition to abnormal levels. Am J Med Genet 61: 154-157.
2. Holding S, Cuckle H. 1994. Maternal serum screening for Down's syndrome taking account of the results of a previous pregnancy. Prenat Diagn 14: 321-322.
3. Larsen SO, Christiansen M, Norgaard-Pedersen B. 1998. Inclusion of serum marker measurements from a previous pregnancy improves Down syndrome screening performance. Prenat Diagn 18: 706-712.
4. Nicolaides KH, Snijders RJM, Cuckle HS. 1998. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat Diagn 18: 519-521.
5. Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH. 1998. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 351: 343-346.
6. Snijders RJM, Sunberg K, Holzgreve W, Henry G, Nicolaides KH. 1999. Maternal age and gestational specific risk for trisomy 21. Ultrasound Obstet Gynecol 13: 167-170.
7. Spencer K. 1997. Between pregnancy biological variability of maternal serum alpha fetoprotein and free beta hCG: implications for Down syndrome screening in subsequent pregnancies. Prenat Diagn 17: 39-45.
8. Spencer K. 2001a. Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies. Prenat Diagn 21: 445-447.
9. Spencer K. 2001b. Evaluation of effect of analytical imprecision in maternal serum screening for Down's syndrome. Ann Clin Biochem 38: 413-414.
10. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
11. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. 2000a. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynaecol 107: 1271-1275.
12. Spencer K, Ong CYT, Liao AWJ, Nicolaides KH. 2000b. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities. Prenat Diagn 20: 491-494.
13. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one stop clinic: a review of three years prospective experience. Brit J Obstet Gynaecol (in press).